What pharmacologic treatments, including biologic agents, are available for axial spondyloarthritis with associated anterior uveitis?

Treatment Options for Axial Spondyloarthritis with Anterior Uveitis

For axial spondyloarthritis patients with recurrent or refractory anterior uveitis, use TNF inhibitor monoclonal antibodies (adalimumab, infliximab, golimumab, or certolizumab) as first-line biologic therapy, and avoid etanercept and IL-17A-only inhibitors (secukinumab, ixekizumab). 1

Pharmacologic Treatment Algorithm

First-Line Therapy

• NSAIDs and physical therapy remain initial treatment for axial disease 2
• However, less than 25% achieve complete symptom control with NSAIDs alone 3

Biologic Selection Based on Uveitis Status

For patients WITH recurrent/refractory uveitis:

1. TNF inhibitor monoclonal antibodies (preferred) 1:

   • Adalimumab (most protective, reduces incident AAU by 67% and recurrent AAU by 20%) 4
   • Infliximab
   • Golimumab
   • Certolizumab pegol 5

2. Avoid these agents:

   • Etanercept - increases incident AAU risk 1.76-fold and recurrent AAU risk 1.42-fold compared to no biologic exposure 4
   • IL-17A-only inhibitors (secukinumab, ixekizumab) - associated with 2.32-fold higher AAU risk versus adalimumab 1 and ranked least effective 6

3. Emerging option - Bimekizumab (dual IL-17A/F inhibitor):

   • Unlike single IL-17A inhibitors, shows protective effects with low uveitis rates (1.2/100 patient-years) 7
   • Most effective in comprehensive analysis for reducing both new-onset and recurrent uveitis 6
   • This represents a critical distinction: blocking IL-17A alone may worsen uveitis, but blocking both IL-17A and IL-17F appears protective

For patients WITHOUT uveitis history:

All approved biologics are options:

• TNF inhibitors (adalimumab, infliximab, golimumab, certolizumab, etanercept)
• IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab)
• JAK inhibitors (tofacitinib, upadacitinib) 2

Treatment Failure Management

Primary failure (no initial response):

• Switch to different mechanism of action 1

Secondary failure (loss of response):

• Either cycle within same class OR switch to different mechanism 1
• For TNF inhibitor failure: IL-17 inhibitors or JAK inhibitors have shown efficacy 1

Available Biologic Classes

TNF Inhibitors

• Monoclonal antibodies: Adalimumab, infliximab, golimumab, certolizumab pegol
• Soluble receptor: Etanercept (avoid in uveitis patients)
• Efficacy: 58-64% achieve ASAS20 response vs 19-38% placebo 3

IL-17 Inhibitors

• IL-17A only: Secukinumab, ixekizumab (avoid in uveitis patients)
• Dual IL-17A/F: Bimekizumab (protective for uveitis)
• Efficacy: 48-61% achieve ASAS20 response vs 18-29% placebo 3

JAK Inhibitors

• Tofacitinib, upadacitinib
• Efficacy: 52-56% achieve ASAS20 response vs 26-29% placebo 3
• Emerging data suggests potential benefit for uveitis prevention 6

Critical Clinical Pitfalls

1. Do not use etanercept in patients with uveitis history - it increases AAU risk 2.5-fold compared to adalimumab 4

2. Do not use single IL-17A inhibitors (secukinumab/ixekizumab) in uveitis patients - they rank worse than placebo for uveitis prevention 6

3. Collaborative ophthalmology management is mandatory - diagnosis and follow-up of AAU must involve an ophthalmologist 1

4. Consider comorbidities in biologic selection:

   • Inflammatory bowel disease: Use TNF inhibitor mAbs, avoid IL-17 inhibitors and NSAIDs 1
   • Heart failure/demyelinating disease: Use IL-17 inhibitors or JAK inhibitors instead of TNF inhibitors 2

Evidence Quality Considerations

The 2023 PANLAR guidelines 1 provide the most current recommendations, strongly endorsing TNF inhibitor monoclonal antibodies for uveitis based on Swedish registry data showing adalimumab as reference with lowest risk. The 2019 ACR guidelines 2 similarly recommend TNF mAbs but predate bimekizumab data. Recent 2024-2025 network meta-analyses 8, 6, 4 consistently demonstrate adalimumab superiority and etanercept inferiority for uveitis prevention, with emerging evidence favoring dual IL-17A/F inhibition over single IL-17A blockade.